197 related articles for article (PubMed ID: 30291223)
1. The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).
Sekeres MA; Swern AS; Giagounidis A; List AF; Selleslag D; Mittelman M; Schlegelberger B; Göhring G; Li JS; Sugrue MM; Fenaux P
Blood Cancer J; 2018 Sep; 8(10):90. PubMed ID: 30291223
[No Abstract] [Full Text] [Related]
2. Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.
Santini V; Fenaux P; Giagounidis A; Platzbecker U; List AF; Haferlach T; Zhong J; Wu C; Mavrommatis K; Beach CL; MacBeth KJ; Almeida A
Leukemia; 2021 Mar; 35(3):897-900. PubMed ID: 32661294
[No Abstract] [Full Text] [Related]
3. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
4. Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.
Mährle T; Akyüz N; Fuchs P; Bonzanni N; Simnica D; Germing U; Asemissen AM; Jann JC; Nolte F; Hofmann WK; Nowak D; Binder M
Haematologica; 2019 Jul; 104(7):1355-1364. PubMed ID: 30655375
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.
Kerdivel G; Chesnais V; Becht E; Toma A; Cagnard N; Dumont F; Rousseau A; Fenaux P; Chevret S; Chapuis N; Boeva V; Fridman WH; Fontenay M; Kosmider O
Leukemia; 2018 Feb; 32(2):558-562. PubMed ID: 28972593
[No Abstract] [Full Text] [Related]
7. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
Abouyahya I; Alhan C; Westers TM; te Boekhorst PA; Kappers-Klunne MC; Coenen JL; Heyning FH; Huls GA; de Wolf JT; Imholz AL; Koene HR; Veth G; de Kruijf EJ; Muus P; Planken EV; Segeren CM; Vasmel WL; van der Velden AM; Velders GA; Koedam J; Ossenkoppele GJ; van de Loosdrecht AA
Leuk Lymphoma; 2013 Apr; 54(4):874-7. PubMed ID: 22971215
[No Abstract] [Full Text] [Related]
8. Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.
Almeida A; Fenaux P; Garcia-Manero G; Goldberg SL; Gröpper S; Jonasova A; Vey N; Castaneda C; Zhong J; Beach CL; Santini V
Leuk Lymphoma; 2018 Sep; 59(9):2135-2143. PubMed ID: 29322849
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
[TBL] [Abstract][Full Text] [Related]
10. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
[No Abstract] [Full Text] [Related]
11. Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
Oka S; Ono K; Nohgawa M
Leuk Lymphoma; 2017 Oct; 58(10):2511-2513. PubMed ID: 28278708
[No Abstract] [Full Text] [Related]
12. The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.
Mohr B; Oelschlaegel U; Thiede C; Stewart MM; Ehninger G; Platzbecker U
Haematologica; 2009 Mar; 94(3):430-1. PubMed ID: 19181778
[No Abstract] [Full Text] [Related]
13. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
[No Abstract] [Full Text] [Related]
14. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
Jonasova A; Neuwirtova R; Polackova H; Siskova M; Stopka T; Cmunt E; Belickova M; Moudra A; Minarik L; Fuchs O; Michalova K; Zemanova Z
Leuk Res; 2018 Jun; 69():12-17. PubMed ID: 29614393
[TBL] [Abstract][Full Text] [Related]
16. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in del 5q MDS: responses and side effects revisited.
Tiu RV; Sekeres MA
Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
[No Abstract] [Full Text] [Related]
18. The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.
Kuendgen A
Leuk Res; 2014 Mar; 38(3):287-8. PubMed ID: 24433864
[No Abstract] [Full Text] [Related]
19. Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.
Jädersten M; Karsan A
Haematologica; 2011 Feb; 96(2):177-80. PubMed ID: 21282717
[No Abstract] [Full Text] [Related]
20. The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.
Santini V; Almeida A; Giagounidis A; Platzbecker U; Buckstein R; Beach CL; Guo S; Altincatal A; Wu C; Fenaux P
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):136-144.e7. PubMed ID: 29429612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
